etherna mRNA/LNP Platform Enters Clinical Trials for Skin Cancer

- The collaboration is structured with Almirall leading clinical development and commercialization, while etherna receives upfront and technology access payments, and is eligible for over €300 million in milestone payments plus tiered royalties. - Intratumoral delivery of the mRNA/LNP platform is designed to produce immunomodulatory proteins directly within the tumor microenvironment, activating tumor-infiltrating dendritic cells and cytotoxic T lymphocytes to fight the cancer locally. This local expression aims to enhance anti-tumor effects while minimizing the systemic toxicity often associated with other cancer therapies. - Etherna’s proprietary technology includes a library of custom lipids for its LNP formulations, which are designed to enable targeted delivery and tailored biodistribution for specific administration routes, including intratumoral injection. In preclinical studies, their LNP formulations have demonstrated a significant outperformance in mRNA expression compared to clinical benchmarks. - A key biomanufacturing challenge for mRNA/LNP therapeutics is the lack of standardized processes compared to more mature biologics like monoclonal antibodies, requiring redevelopment for each new formulation. Key process hurdles include the shear sensitivity of LNPs during purification, ensuring high encapsulation efficiency to prevent degradation and immune reactions, and removing impurities like double-stranded RNA. - To address manufacturing complexities, the industry is increasingly adopting Process Analytical Technology (PAT) for real-time monitoring of critical quality attributes during in-vitro transcription and LNP formulation. The integration of PAT with digital twin platforms allows for predictive, adaptive control, which can reduce development cycles and prevent batch failures in a GMP environment. - This collaboration is part of Almirall's broader R&D strategy to become a leader in medical dermatology by leveraging external innovation to complement its internal capabilities. The company is modality-agnostic, selecting the best technology to address unmet needs in its focus areas. - The cell and gene therapy CDMO market has recently experienced a rapid expansion in manufacturing capacity that has outpaced the number of clinical trials, leading to an imbalance. This makes strategic partnerships between tech platform companies and pharmaceutical firms crucial for navigating the competitive landscape. - The biotech funding climate for mRNA technologies has shifted, with some government funding for vaccine development being reduced. However, venture financing continues to flow into the development of mRNA-based *therapeutics* for indications like oncology, signaling investor confidence in the platform's potential beyond infectious diseases.